International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 53

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 53

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 53

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

abataceptum

abatacept

1-25-oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimolecular (146→146')-disulfide

abatacept

(146→146')-disulfure bimoléculaire de [Gln^{151},Ser^{156},Ser^{162},Ser^{165},Ser^{174}] (protéine de fusion entre le précurseur de l'oncostatine M humaine-(1-25)-peptide (séquence signal), la protéine 4 cytotoxique du lymphocyte-T humaine-[2-126]-peptide (partie extracellulaire de l'antigène CD152) et le peptide de 233 résidus fragment *C*-terminal de la chaîne lourde de l'immunoglobuline G1 humaine)

abatacept

1-25-oncostatina M (precursor humano) proteína da fusión con CTLA-4 (antígeno) (humano) proteína da fusión con inmunoglobulina G1 (fragmento humano de la pesada cadena), bimolecular (146→146')-disulfido

$C_{3750}H_{5872}N_{982}O_{1154}S_{38}$



* glycosylation site
* sites de glycosylation
* posiciones de glicosilación

acotiamidum

acotiamide	*N*-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]thiazol-4-carboxamide
acotiamide	*N*-[2-[bis(1-méthyléthyl)amino]éthyl]-2-[(2-hydroxy-4,5-diméthoxybenzoyl)amino]thiazol-4-carboxamide
acotiamida	*N*-[2-[bis(1-metiletil)amino]etil]-2-[(2-hidroxi-4,5-dimetoxibenzoil)amino]tiazol-4-carboxamida

$C_{21}H_{30}N_4O_5S$



alagebrium chloridum

alagebrium chloride	4,5-dimethyl-3-(2-oxo-2-phenylethyl)thiazolium chloride
chlorure d'alagébrium	chlorure de 4,5-diméthyl-3-(2-oxo-2-phényléthyl)thiazolium
cloruro de alagebrio	cloruro de 4,5-dimetil-3-(2-fenil-2-oxoetil)tiazolio

$C_{13}H_{14}ClNOS$



alglucosidasum alfa

alglucosidase alfa	human lysosomal prepro-α-glucosidase-(57-952)-peptide 199-arginine-223-histidine variant
alglucosidase alfa	199-arginine-223-histidine variant du (57-952)-peptide de la prépro-α-glucosidase lysosomale humaine
alglucosidasa alfa	199-arginina-223-histidina variante del (57-952)-peptido de la prepro-α-glucosidasa lysosómica humana

$C_{4490}H_{6823}N_{1197}O_{1298}S_{32}$

QQGASRPGPR DAQAHPGRPR AVPTQCDVPP NSRFDCAPDK
AITQEQCEAR GCCYIPAKQG LQGAQMGQPW CFFPPSYPSY
KLEN*LSSSEM GYTATLTRTT PTFFPKDILT LRLDVMMETE
NRLHFTIKDP ANRRYEVPLE TPRVHSRAPS PLYSVEFSEE
PFGVIVHRQL DGRVLLN*TTV APLFFADQFL QLSTSLPSQY
ITGLAEHLSP LMLSTSWTRI TLWNRDLAPT PGANLYGSHP
FYLALEDGGS AHGVFLLNSN AMDVVLQPSP ALSWRSTGGI
LDVYIFLGPE PKSVVQQYLD VVGYPFMPPY WGLGFHLCRW
GYSSTAITRQ VVEN*MTRAHF PLDVQWNDLD YMDSRRDFTF
NKDGFRDFPA MVQELHQGGR RYMMIVDPAI SSSGPAGSYR
PYDEGLRRGV FITN*ETGQPL IGKVWPGSTA FPDFTNPTAL
AWWEDMVAEF HDQVPFDGMW IDMNEPSNFI RGSEDGCPNN
ELENPPYVPG VVGGTLQAAT ICASSHQFLS THYNLHNLYG
LTEAIASHRA LVKARGTRPF VISRSTFAGH GRYAGHWTGD
VWSSWEQLAS SVPEILQFNL LGVPLVGADV CGFLGN*TSEE
LCVRWTQLGA FYPFMRNHNS LLSLPQEPYS FSEPAQQAMR
KALTLRYALL PHLYTLFHQA HVAGETVARP LFLEFPKDSS
TWTVDHQLLW GEALLITPVL QAGKAEVTGY FPLGTWYDLQ
TVPIEALGSL PPPPAAPREP AIHSEGQWVT LPAPLDTINV
HLRAGYIIPL QGPGLTTTES RQQPMALAVA LTKGGEARGE
LFWDDGESLE VLERGAYTQV IFLARN*NTIV NELVRVTSEG
AGLQLQKVTV LGVATAPQQV LSNGVPVSN*F TYSPDTKVLD
ICVSLLMGEQ FLVSWC

* glycosylation sites
* sites de glycosylation
* posiciones de glicosilación

armodafinilum
armodafinil 2-[(*R*)-(diphenylmethyl)sulfinyl]acetamide

armodafinil (-)-2-[(*R*)-(diphénylméthyl)sulfinyl]acétamide

armodafinilo (-)-2-[(*R*)-(difenilmetil)sulfinil]acetamida

$C_{15}H_{15}NO_2S$



bamirastinum

bamirastine — 2-[6-({3-[4-(diphenylmethoxy)piperidin-1-yl]propyl}amino)imidazo=[1,2-b]pyridazin-2-yl]-2-methylpropanoic acid

bamirastine — acide 2-[6-[[3-[4-(diphénylméthoxy)pipéridin-1-yl]propyl]amino]=imidazo[1,2-*b*]pyridazin-2-yl]-2-méthylpropanoïque

bamirastina — ácido 2-[6-[[3-[4-(difenilmetoxi)piperidin-1-il]propil]amino]imidazo=[1,2-*b*]piridazin-2-il]-2-metilpropanoico

$C_{31}H_{37}N_5O_3$



befetupitantum

befetupitant — 2-[3,5-bis(trifluomethyl)phenyl]-*N*,2-dimethyl-*N*-[4-(2-methylphenyl)-6-(morpholin-4-yl)pyridin-3-yl]propanamide

béfétupitant — 2-[3,5-bis(trifluométhyl)phényl]-*N*,2-diméthyl-*N*-[4-(2-méthylphényl)-6-(morpholin-4-yl)pyridin-3-yl]propanamide

befetupitant — 2-[3,5-bis(trifluometil)fenil]-*N*,2-dimetil-*N*-[4-(2-metilfenil)-6-(morfolin-4-il)piridin-3-il]propanamida

$C_{29}H_{29}F_6N_3O_2$



belotecanum

belotecan — (4*S*)-4-ethyl-4-hydroxy-11-[2-(isopropylamino)ethyl]-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*)-dione

bélotécan — (4*S*)-4-éthyl-4-hydroxy-11-[2-[(1-méthyléthyl)amino]éthyl]-1,12-dihydro-14*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléine-3,14(4*H*)-dione

belotecán — (4*S*)-4-etil-4-hidroxi-11-[2-(isopropilamino)etil]-1,12-dihidro-14*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolina-3,14(4*H*)-diona

$C_{25}H_{27}N_3O_4$



carmoterolum

carmoterol	8-hydroxy-5-[(1*R*)-1-hydroxy-2-{[(1*R*)-2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl]quinolin-2(1*H*)-one
carmotérol	8-hydroxy-5-[(1*R*)-1-hydroxy-2-[[(1*R*)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]quinoléin-2(1*H*)-one
carmoterol	8-hidroxi-5-[(1*R*)-1-hidroxi-2-[[(1*R*)-2-(4-metoxifenil)-propan-2-il]amino]etil]quinolin-2(1*H*)-ona

$C_{21}H_{24}N_2O_4$



cetilistatum

cetilistat	2-(hexadecyloxy)-6-methyl-4*H*-3,1-benzoxazin-4-one
cétilistat	2-(hexadécyloxy)-6-méthyl-4*H*-3,1-benzoxazin-4-one
cetilistat	2-(hexadeciloxi)-6-metil-4*H*-3,1-benzoxazin-4-ona

$C_{25}H_{39}NO_3$



dasantafilum

dasantafil	7-(3-bromo-4-methoxyphenylmethyl)-1-ethyl-8-{[(1*R*,2*R*)-2-hydroxycyclopropyl]amino}-3-(2-hydroxyethyl)-3,7-dihydro-1*H*-purine-2,6-dione
dasantafil	7-(3-bromo-4-méthoxybenzyl)-1-éthyl-8-[[(1*R*,2*R*)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyéthyl)-3,7-dihydro-1*H*-purine-2,6-dione
dasantafilo	7-(3-bromo-4-metoxibencil)-1-etil-8-[[(1*R*,2*R*)-2-hidroxiciclopentil]=amino]-3-(2-hidroxietil)-3,7-dihidro-1*H*-purina-2,6-diona

$C_{22}H_{28}BrN_5O_5$



deluceminum

delucemine	3,3-bis(3-fluorophenyl)-*N*-methylpropan-1-amine
délucémine	3,3-bis(3-fluorophényl)-*N*-méthylpropan-1-amine
delucemina	3,3-bis(3-fluorofenil)-*N*-metilpropan-1-amina

$C_{18}H_{27}N_5O_{21}P_4$



denufosolum

denufosol	2'-deoxycytidine(5')tetraphospho(5')uridine
dénufosol	2'-désoxycytidine(5')tétraphospho(5')uridine
denufosol	2'-desoxicitidina(5')tetrafosfo(5')uridina

$C_{18}H_{27}N_5O_{21}P_4$



depelestatum

depelestat — human recombinant neutrophil elastase inhibitor, homologue of the second Kunitz domain of Inter-alpha-trypsin inhibitor light chain: [Glu^{285},Ile^{297},Phe^{300},Pro^{301},Arg^{302}]AMBP protein precursor-(285-340)-peptide (human)

dépélestat — [Glu^{285},Ile^{297},Phe^{300},Pro^{301},Arg^{302}]précurseur de la protéine AMBP humaine-(285-340)-peptide, homologue du second domaine Kunitz de la chaîne légère de l'inhibiteur de l'Inter-alpha-trypsine, inhibiteur de l'élastase neutrophile

depelestat — [Glu^{285},Ile^{297},Phe^{300},Pro^{301},Arg^{302}]precursor de la proteína AMBP humana-(285-340)-péptido, homólogo del segundo dominio Kunitz de la cadena ligera del inhibidor de la Inter-alfa-tripsina, inhibidor de la elastasa neutrófila

$C_{282}H_{412}N_{74}O_{75}S_6$



dirlotapidum

dirlotapide — *N*-{(1*S*)-2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)biphenyl-2-carboxamido]-1*H*-indol-2-carboxamide

dirlotapide — *N*-[(1*S*)-2-(benzylméthylamino)-2-oxo-1-phényléthyl]-1-méthyl-5-[[[4'-(trifluorométhyl)biphényl-2-yl]carbonyl]amino]-1*H*-indole-2-carboxamide

dirlotapida — *N*-[(1*S*)-2-(bencilmetilamino)-2-oxo-1-feniletil]-1-metil-5-[[[4'-(trifluorometil)bifenil-2-il]carbonil]amino]-1*H*-indol-2-carboxamida

$C_{40}H_{33}F_3N_4O_3$



edaglitazonum

edaglitazone — (5*RS*)-5-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}methyl)-1,3-thiazolidine-2,4-dione

édaglitazone — (5*RS*)-5-[[4-[2-(5-méthyl-2-phényloxazol-4-yl)éthoxy]-1-benzothiophén-7-yl]méthyl]thiazolidine-2,4-dione

edaglitazona — (5*RS*)-5-[[4-[2-(2-fenil-5-metiloxazol-4-il)etoxi]-1-benzotiofen-7-il]metil]tiazolidina-2,4-diona

$C_{24}H_{20}N_2O_4S_2$



and enantiomer
et énantiomère
y enantiómero

eslicarbazepinum

eslicarbazepine — (10*S*)-10-hydroxy-10,11-dihydro-5*H*-dibenzo[*b,f*]azepin-5-carboxamide

eslicarbazépine — (10*S*)-10-hydroxy-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azépin-5-carboxamide

eslicarbazepina — (10*S*)-10-hidroxi-10,11-dihidro-5*H*-dibenzo[*b*,*f*]azepin-5-carboxamida

$C_{15}H_{14}N_2O_2$



exbivirumabum

exbivirumab — immunoglobulin G, anti-(hepatitis B surface antigen) (human monoclonal 19.79.5 heavy chain), disulfide with human monoclonal 19.79.5 λ chain, dimer

exbivirumab — immunoglobuline G, anti-(antigène de surface du virus de l'hépatite B) dimère du disulfure entre la chaîne lourde et la chaîne λ de l'anticorps monoclonal humain 19.79.5

exbivirumab — inmunoglobulina G, anti-(antígeno de superficie del virus de la hepatitis B) dímero del disulfuro entre la cadena pesada y la cadena λ del anticuerpo monoclonal humano 19.79.5

$C_{6416}H_{9924}N_{1732}O_{1982}S_{44}$

fampronilum

fampronil — 2-{5-chloro-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-3-methyl-1*H*-pyrazol-4-yl}-1*H*-imidazole-4,5-dicarbonitrile

fampronil — 2-[5-chloro-1-[2,6-dichloro-4-(trifluorométhyl)phényl]-3-méthyl-1*H*-pyrazol-4-yl]-1*H*-imidazole-4,5-dicarbonitrile

fampronilo — 2-[5-cloro-1-[2,6-dicloro-4-(trifluorometil)fenil]-3-metil-1*H*-pirazol-4-il]-1*H*-imidazol-4,5-dicarbonitrilo

$C_{16}H_6Cl_3F_3N_6$



fidexabanum

fidexaban — {[2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-{3-[1-methyl-4,5-dihydro-1*H*-imidazol-2-yl]phenoxy}pyridin-4-yl]methylamino}= acetic acid

fidexaban — acide [[2-(5-carbamimidoyl-2-hydroxyphénoxy)-3,5-difluoro-6-[3-(1-méthyl-4,5-dihydro-1*H*-imidazol-2-yl)phénoxy]pyridin-4-yl]méthylamino]acétique

fidexabán — ácido [[2-(5-carbamimidoil-2-hidroxifenoxi)-3,5-difluoro-6-[3-(1-metil-4,5-dihidro-1*H*-imidazol-2-il)fenoxi]piridin-4-il]metilamino]acético

$C_{25}H_{24}F_2N_6O_5$



fingolimodum

fingolimod — 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol

fingolimod — 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol

fingolimod — 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol

$C_{19}H_{33}NO_2$



gadodenteratum

gadodenterate

10,10',10'',10''',10'''',10''''',10'''''',10''''''',10'''''''',10''''''''',10'''''''''',10''''''''',10'''''''''',10''''''''''',10'''''''''''',10''''''''''''',10'''''''''''''',10''''''''''''''',10'''''''''''''''',10''''''''''''''''-(benzene-1,3,5-triyltris(carbonylnitrilobis{(ethan-2,1-diylimino)[(5*S*)-6-oxohexane-6,1,5-triyl]bis(imino[(5S)-6-oxohexane-6,1,5-triyl]bis{(2-oxoethane-2,1-diyl)imino[(2*S*)-1-oxopropane-1,2-diyl]})]})}tetracosakis[1,4,7,10-tetraazacyclodecane-1,4,7-triacetato(3–)gadolinium(III)]

gadodentérate

10,10',10'',10''',10'''',10''''',10'''''',10''''''',10'''''''',10''''''''',10'''''''''',10''''''''',10'''''''''',10''''''''''',10'''''''''''',10''''''''''''',10'''''''''''''',10''''''''''''''',10'''''''''''''''',10''''''''''''''''-[benzène-1,3,5-triyltris[carbonylnitrilobis[éthylèneimino=[(5S)-6-oxohexane-6,1,5-triyl]bis[imino[(5S)-6-oxohexane-6,1,5-triyl]bis[imino(2-oxoéthylène)imino(1-méthyl-2-oxoéthylène)]]]]]tétracosakis[[1,4,7,10-tétraazacyclododécane-1,4,7-triacétato(3-)]gadolinium]

gadodenterato

10,10',10'',10''',10'''',10''''',10'''''',10''''''',10'''''''',10''''''''',10'''''''''',10''''''''',10'''''''''',10''''''''''',10'''''''''''',10''''''''''''',10'''''''''''''',10''''''''''''''',10'''''''''''''''',10''''''''''''''''-[benceno-1,3,5-triiltris[carbonilnitrilobis[etilenoimino=[(5*S*)-6-oxohexano-6,1,5-triil]bis[imino[(5*S*)-6-oxohexano-6,1,5-triil]]bis[imino(2-oxoetileno)imino(1-metil-2-oxoetileno)]]]]tetracosakis[[1,4,7,10-tetraazaciclododecano-1,4,7-triacetato(3-)]gadolinio]

$C_{585}H_{927}Gd_{24}N_{165}O_{213}$



gantacurium chloridum

gantacurium chloride

(1*R*,2*S*)-2-(3-{[(2*Z*)-2-chloro-4-{3-[(1*S*,2*R*)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propoxy}-4-oxobut-2-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolinium dichloride

chlorure de gantacurium

dichlorure de (1*R*,2*S*)-2-[3-[[(2*Z*)-2-chloro-4-[3-[(1*S*,2*R*)-6,7-diméthoxy-2-méthyl-1-(3,4,5-triméthoxyphényl)-1,2,3,4-tétrahydroisoquinoléinio]propoxy]-4-oxobut-2-énoyl]oxy]propyl]-6,7-diméthoxy-2-méthyl-1-(3,4,5-triméthoxybenzyl)-1,2,3,4-tétrahydroisoquinoléinium

cloruro de gantacurio

dicloruro de (1*R*,2*S*)-2-[3-[[(2*Z*)-2-cloro-4-[3-[(1*S*,2*R*)-2-metil-6,7-dimetoxi-1-(3,4,5-trimetoxifenil)-1,2,3,4-tetrahidroisoquinolinio]=propoxi]-4-oxobut-2-enoil]oxi]propil]-2-metil-6,7-dimetoxi-1-(3,4,5-trimetoxibencil)-1,2,3,4-tetrahidroisoquinolinio

$C_{53}H_{69}Cl_3N_2O_{14}$



golimumabum

golimumab

immunoglobulin G1, anti-(human tumor necrosis factor α) (human monoclonal CNTO 148 γ1-chain), disulfide with human monoclonal CNTO 148 κ-chain, dimer

golimumab

immunoglobuline G1, anti-(facteur α de nécrose tumorale humain) dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal humain CNTO 148

golimumab

inmunoglobulina G1, anti-(factor α de necrosis tumoral humano) dímero del disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal humano CNTO 148

$C_{6530}H_{10068}N_{1752}O_{2026}S_{44}$

idronoxilum

idronoxil

3-(4-hydroxyphenyl)-2*H*-chromen-7-ol

idronoxil

3-(4-hydroxyphényl)-2*H*-1-benzopyran-7-ol

idronoxilo

3-(4-hidroxifenil)-2*H*-1-benzopiran-7-ol

$C_{15}H_{12}O_3$



imiglitazarum

imiglitazar	(4*E*)-4-[({4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl}= methoxy)imino]-4-phenylbutanoic acid
imiglitazar	acide (4*E*)-4-[[[4-[(5-méthyl-2-phényloxazol-4-yl)méthoxy]benzyl]= oxy]imino]-4-phénylbutanoïque
imiglitazar	ácido (4*E*)-4-[[[4-[(2-fenil-5-metiloxazol-4-il)metoxi]bencil]oxi]imino]-4-fenilbutanoico

$C_{28}H_{26}N_2O_5$



indacaterolum

indacaterol	5-{(1*R*)-2-[(5,6-diethyl-2,3-dihydro-1*H*-inden-2-yl)amino] -1-hydroxyethyl}-8-hydroxyquinolin-2(1*H*)-one
indacatérol	5-[(1*R*)-2-[(5,6-diéthyl-2,3-dihydro-1*H*-indén-2-yl)amino]-1-hydroxyéthyl]-8-hydroxyquinoléin-2(1*H*)-one
indacaterol	5-[(1*R*)-2-[(5,6-dietil-2,3-dihidro-1*H*-inden-2-il)amino]-1-hidroxietil]-8-hidroxiquinolin-2(1*H*)-ona

$C_{24}H_{28}N_2O_3$



indibulinum

indibulin	2-[1-(4-chlorophenylmethyl)-1*H*-indol-3-yl]-2-oxo-*N*-(pyridin-4-yl)acetamide
indibuline	2-[1-(4-chlorobenzyl)-1*H*-indol-3-yl]-2-oxo-*N*-(pyridin-4-yl)acétamide
indibulina	2-[1-(4-clorobencil)-1*H*-indol-3-il]-2-oxo-*N*-(piridin-4-il)acetamida

$C_{22}H_{16}ClN_3O_2$



ismomultinum alfa

ismomultin alfa — 47-261-Glycoprotein gp 39 (human clone CDM8-gp39 reduced)

ismomultine alfa — [290-isoleucine]glycoprotéine 39 constituant du cartilage humain (glycoforme alfa)

ismomultina alfa — fragmento 47-261 de la glicoproteina 39 constituyente del cartílago humano (variante [Arg^{124}] producida por el clon humano CDM8-gp39)

$C_{1827}H_{2785}N_{493}O_{530}S_{11}$

YKLVCYYTSW SQYREGDGSC FPDALDRFLC THIIYSFAN*I
SNDHIDTWEW NDVTLYGMLN TLKNRNPNLK TLLSVGGWNF
GSQRFSKIAS NTQSRRTFIK SVPPFLRTHG FDGLDLAWLY
PGRRDKQHFT TLIKEMKAEF IKEAQPGKKQ LLLSAALSAG
KVTIDSSYDI AKISQHLDFI SIMTYDFHGA WRGTTGHHSP
LFRGQEDASP DRFSNTDYAV GYMLRLGAPA SKLVMGIPTF
GRSFTLASSE TGVGAPISGP GIPGRFTKEA GTLAYYEICD
FLRGATVHRI LGQQVPYATK GNQWVGYDDQ ESVKSKVQYL
KDRQLAGAMV WALDLDDFQG SFCGQDLRFP LTNAIKDALA
AT

* glycosylation site
* sites de glycosylation
* posiciones de glicosilación

lanimostimum

lanimostim — 4-221-colony-stimulating factor 1 (human clone p3ACSF-69 reduced)

lanimostim — facteur-1 de stimulation de colonie de macrophage humain-(4-221)-peptide (clone humain p3ACSF-69)

lanimostim — factor-1 de la estímulo de colonia de macrófago humano -(4-221)-péptido (clon humano p3ACSF-69)

$C_{2146}H_{3346}N_{572}O_{686}S_{28}$

[SEYCSHM IGSGHLQSLQ RLIDSQMETS CQITFEFVDQ
EQLKDPVCYL KKAFLLVQDI MEDTMRFRDN TPNAIAIVQL
QELSLRLKSC FTKDYEEHDK ACVRTFYETP LQLLEKVKNV
FNETKNLLDK DWNIFSKNCN NSFAECSSQD VVTKPDCNCL
YPKAIPSSDP ASVSPHQPLA PSMAPVAGLT WEDSEGTEGS
SLLPGEQPLH TVDPGSAKQR P]$_2$

lemuteporfinum

lemuteporfin — dimethyl (2*RS*,2^1*SR*)-8-ethenyl-13,17-bis=[3-(2-hydroxyethoxycarbonyl)-3-oxopropyl]-2,7,12,18-tetramethyl-2,2^1-dihydrobenzo[b]porphyrin-2^1,2^2-dicarboxylate

lémutéporfine — *trans*-8-éthényl-13,17-bis[3-(2-hydroxyéthoxy)-3-oxopropyl]-2,7,12,18-tétraméthyl-2,2^1-dihydrobenzo[*b*]porphyrine-2^1,2^2-dicarboxylate de diméthyle

lemuteporfina — *trans*-8-etenil-13,17-bis[3-(2-hidroxietoxi)-3-oxopropil]-2,7,12,18-tetrametil-2,2^1-dihidrobenzo[*b*]porfirine-2^1,2^2-dicarboxylate de dimetilo

$C_{44}H_{48}N_4O_{10}$



lenalidomidum

lenalidomide — (3*RS*)-3-(4-amino-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl)piperidine-2,6-dione

lénalidomide — (3*RS*)-3-(4-amino-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl)pipéridine-2,6-dione

lenalidomide — (3*RS*)-3-(4-amino-1-oxo-1,3-dihidro-2*H*-isoindol-2-il)piperidina-2,6-diona

$C_{13}H_{13}N_3O_3$



and enantiomer
et énantiomère
y enantiómero

lestaurtinibum

lestaurtinib — (9*S*,10*S*,12*R*)-10-hydroxy-10-(hydroxymethyl)-9-methyl-2,3,9,10,11,12-hexahydro-1*H*-9,12-epoxydiindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo=[3,4-*i*][1,6]benzodiazocin-1-one

lestaurtinib — (9*S*,10*S*,12*R*)-10-hydroxy-10-(hydroxyméthyl)-9-méthyl-2,3,9,10,11,12-hexahydro-9,12-époxy-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo=3,4-*i*][1,6]benzodiazocin-1-one

lestaurtinib — (9*S*,10*S*,12*R*)-10-hidroxi-10-(hidroximetil)-9-metil-2,3,9,10,11,12-hexahidro-9,12-epoxi-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pirrolo=[3,4-*i*][1,6]benzodiazocin-1-ona

$C_{26}H_{21}N_3O_4$



libivirumabum

libivirumab — immunoglobulin G, anti- (hepatitis B surface antigen)(human monoclonal 17.1.41 heavy chain), disulfide with human monoclonal 17.1.41 κ-chain, dimer

libivirumab — immunoglobuline G, anti-(antigène de surface du virus de l'hépatite B) ; dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal humain 17.1.41

libivirumab — inmunoglobulina G, anti-(antígeno de superficie del virus de la hepatitis B) ; dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal humano 17.1.41

$C_{6598}H_{10232}N_{1788}O_{2060}S_{46}$

maravirocum

maraviroc — isopropyl, 4,4-difluoro-*N*-[(1*S*)-3-{(1*R*,3*s*,5*S*)-3-[3-methyl-5-(propan-2-yl)-4*H*-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]cyclohexanecarboxamide

maraviroc — 4,4-difluoro-*N*-[(1*S*)-3-[(1*R*,3*s*,5*S*)-3-[3-méthyl-5-(1-méthyléthyl)-4*H*-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phénylpropyl]=cyclohexanecarboxamide

maraviroc — 4,4-difluoro-*N*-[(1*S*)-1-fenil-3-[(1*R*,3*s*,5*S*)-3-[3-isopropil-5-metil-4*H*-1,2,4-triazol-4-il]-8-azabiciclo[3.2.1]oct-8-il] propil]=ciclohexanocarboxamida

$C_{29}H_{41}F_2N_5O$



mecaserminum rinfabas

mecasermin rinfabate	insulin-like growth factor I (human), complex with insulin-like growth factor-binding protein IGFBP-3 (human)
mécasermine rinfabate	facteur I de croissance humain analogue à l'insuline (mécasermine) lié à la [5-alanine]protéine-3 humaine se liant au facteur de croissance analogue à l'insuline (IGFBP-3 humaine)
mecasermina rinfabato	factor I del crecimiento humano semejante a la insulina (mecasermina) unida a la [5-alanina]proteína-3 humana unida con el factor de crecimiento similar a la insulina (IGFBP-3 humana)

$C_{1231}H_{1967}N_{371}O_{384}S_{20}$

```
GPETLCGAEL VDALQFVCGD RGFYFNKPTG YGSSSRRAPQ
TGIVDECCFR SCDLRRLEMY CAPLKPAKSA

GASSAGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC
GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL
LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG
SVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK
VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL
NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK
YGQPLPGYTT KGKEDVHCYS MQSK
```

milataxelum

milataxel	1,10β-dihydroxy-9-oxo-5β,20-epoxy-3ζ-tax-11-ene-2α,4,7β,13α-tetrayl 4-acetate 2-benzoate 13-[(2*R*,3*R*)-3-(*tert*-butoxycarbonylamino)-3-(furan-2-yl)-2-hydroxypropanoate] 7-propanoate
milataxel	12b-acétate, 12-benzoate, 9-[(2*R*,3*R*)-3-[[(1,1-diméthyléthoxy)carbonyl]amino]-3-(furan-2-yl)-2-hydroxypropanoate] et 4-propanoate de (2a*R*,4*S*,4a*S*,6*R*,7*E*,9*S*,11*S*,12*S*,12b*S*)-6,11-dihydroxy-4a,8,13,13-tétraméthyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-décahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxète-4,9,12,12b(2a*H*)-tétrayle
milataxel	12b-acetato, 12-benzoato, 9-[(2*R*,3*R*)-3-[[(1,1-dimetiletoxi)carbonil]amino]-3-(furan-2-il)-2-hidroxipropanoato] y 4-propanoato de (2a*R*,4*S*,4a*S*,6*R*,7*E*,9*S*,11*S*,12*S*,12b*S*)-6,11-dihidroxi-4a,8,13,13-tetrametil-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahidro-7,11-metano-1*H*-ciclodeca[3,4]benzo[1,2-*b*]oxeto-4,9,12,12b(2a*H*)-tetrail

$C_{44}H_{55}NO_{16}$



mirococeptum

mirococept	protein APT070 (synthetic human clone pET04-01 complement receptor type 1 short consensus repeat 1-3 fragment), (198→17')-disulfide with *N*-(tetradecanoyl)glycyl-L-seryl-L-seryl-L-lysyl-L-seryl-L-prolyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-prolylglycyl-L-aspartyl-L-cysteinamide
mirococept	(238-17')-disulfure entre le [41-méthionyl]précurseur du récepteur de type 1 du complément-(41-238)-peptide et le (*N*-tétradécanoylglycyl)-L-séryl-L-séryl-L-lysyl-L-séryl-L-prolyl-L-séryl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-prolylglycyl-L-aspartyl-L-cystéinamide
mirococept	(238-17')-disulfuro entre el [41-metionil]precursor del receptor de tipo 1 del complemento -(41-238)- péptido y el (*N*-tetradecanoilglicil)-L-seril-L-seril-L-lisil-L-seril-L-prolil-L-seril-L-lisil-L-lisil-L-lisil-L-lisil-L-lisil-L-prolilglicil-L-aspartil-L-cisteinamida

$C_{1054}H_{1635}N_{293}O_{312}S_{16}$



paclitaxelum ceribas

paclitaxel ceribate

7β-[(2*RS*)-2,3-dihydroxypropoxycarbonyloxy]-1-hydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,10β,13α-tetrayl 4,10-diacetate 2-benzoate 13-[(2*R*,3*S*)-3-benzamido-2-hydroxy-3-phenylpropanoate]

céribate de paclitaxel

6,12b-diacétate, 12-benzoate, 4-[[(2*RS*)-2,3-dihydroxypropoxy]= carboxylate] et 9-[(2*R*,3*S*)-3-(benzoylamino)-2-hydroxy-3-phénylpropanoate] de (2a*R*,4*S*,4a*S*,6*R*,7*E*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-11-hydroxy-4a,8,13,13-tétraméthyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-décahydro-7,11-méthano-1*H*-cyclodéca[3,4]benzo[1,2-*b*]oxète-4,6,9,12,12b(2a*H*)-pentayle

ceribato de paclitaxel

6,12b-diacetato, 12-benzoato, 4-[[(2*RS*)-2,3-dihidroxipropoxi]= carboxilato] y 9-[(2*R*,3*S*)-3-(benzoilamino)-3-fenilpropanoato-2-hidroxi] de (2a*R*,4*S*,4a*S*,6*R*,7*E*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-11-hidroxi-4a,8,13,13-tetrametil-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahidro-7,11-metano-1*H*-ciclodeca[3,4]benzo[1,2-*b*]oxeto-4,6,9,12,12b(2a*H*)-pentailo

$C_{51}H_{57}NO_{18}$



palosuranum

palosuran

1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea

palosuran

1-[2-(4-benzyl-4-hydroxypipéridin-1-yl)éthyl]-3-(2-méthylquinoléin-4-yl)urée

palosurán

1-[2-(4-bencil-4-hidroxipiperidin-1-il)etil]-3-(2-metilquinolin-4-il)urea

$C_{25}H_{30}N_4O_2$



panitumumabum

panitumumab — immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal ABX-EGF heavy chain), disulfide with human monoclonal ABX-EGF light chain, dimer

panitumumab — immunoglobuline, anti-(récepteur du facteur de croissance épidermal humain) dimére du disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal humain ABX-EGF

panitumumab — inmunoglobulina, anti-(receptor del factor de crecimiento epidérmico humano) dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humano ABX-EGF

$C_{6306}H_{9732}N_{1672}O_{1994}S_{46}$

pegamotecanum

pegamotecan — α-{2-[(2*S*)-1-{[(4*S*)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl]oxy}-1-oxopropan-2-ylamino]-2-oxoethyl}-ω-(2-[(2*S*)-1-{[(4*S*)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl]oxy}-1-oxopropan-2-ylamino]-2-oxoethoxy)poly(oxyethane-1,2-diyl)

pégamotécan — dérivé pégylé de la camptothécine obtenu par amidification entre le (2*S*)-2-aminopropanoate de (4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle (L-alaninate de camptothécine) et le α-(carboxyméthyl)-ω-(carboxyméthoxy)poly(oxyéthylène)

pegamotecán — derivado pegilado de la camptotecina obtenido por amidificación entre el (2*S*)-2-aminopropanoato de (4*S*)-4-etil-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-ilo (L-alaninato de camptotecina) y el α-(carboximetil)-ω-(carboximetoxi)poli(oxietileno)

$C_{50}H_{44}N_6O_{13}\ [C_2H_4O]_n$



pelitinibum

pelitinib — (2*E*)-*N*-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)but-2-enamide

pélitinib — (2*E*)-*N*-[4-[(3-chloro-4-fluorophényl)amino]-3-cyano-7-éthoxyquinoléin-6-yl]-4-(diméthylamino)but-2-énamide

pelitinib — (2*E*)-*N*-[4-[(3-cloro-4-fluorofenil)amino]-3-ciano-7-etoxiquinolin-6-il]-4-(dimetilamino)but-2-enamida

$C_{24}H_{23}ClFN_5O_2$



perflubutanum

perflubutane	1,1,1,2,2,3,3,4,4,4-decafluorobutane
perflubutane	décafluorobutane
perflubutano	decafluorobutano

C_4F_{10}



perzinfotelum

perzinfotel	[2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]= phosphonic acid
perzinfotel	acide [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-én-2-yl)éthyl]= phosphonique
perzinfotel	ácido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)etil]= fosfónico

$C_9H_{13}N_2O_5P$



prasugrelum

prasugrel	5-[(1*RS*)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-*c*]pyridin-2-yl acetate
prasugrel	acétate de 5-[(1*RS*)-2-cyclopropyl-1-(2-fluorophényl)-2-oxoéthyl]-4,5,6,7-tétrahydrothiéno[3,2-*c*]pyridin-2-yle
prasugrel	acetato de 5-[(1*RS*)-2-ciclopropil-1-(2-fluorofenil)-2-oxoetil]-4,5,6,7-tetrahidrotieno[3,2-*c*]piridin-2-ilo

$C_{20}H_{20}FNO_3S$



and enantiomer
et énantiomère
y enantiómero

radafaxinum

radafaxine (2*S*,3*S*)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol

radafaxine (+)-(2*S*,3*S*)-2-(3-chlorophényl)-3,5,5-triméthylmorpholin-2-ol

radafaxina (+)-(2*S*,3*S*)-2-(3-clorofenil)-3,5,5-trimetilmorfolin-2-ol

$C_{13}H_{18}ClNO_2$



ranirestatum

ranirestat (3*R*)-2'-(4-bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4'(1'*H*)-pyrrolo[1,2-*a*]pyrazine]-1',2,3',5(2'*H*)-tetrone

ranirestat (-)-(3*R*)-2'-(4-bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4'(1'*H*)-pyrrolo[1,2-*a*]pyrazine]-1',2,3',5(2'*H*)-tétrone

ranirestat (-)-(3*R*)-2'-(4-bromo-2-fluorobencil)espiro[pirrolidina-3,4'(1'*H*)-pirrolo[1,2-*a*]pirazina]-1',2,3',5(2'*H*)-tetrona

$C_{17}H_{11}BrFN_3O_4$



regadenosonum

regadenoson 1-(6-amino-9-β-D-ribofuranosyl-9*H*-purin-2-yl)-*N*-methyl-1*H*-pyrazole-4-carboxamide

régadénoson 1-(6-amino-9-β-D-ribofuranosyl-9*H*-purin-2-yl)-*N*-méthyl-1*H*-pyrazole-4-carboxamide

regadenosón 1-(6-amino-9-β-D-ribofuranosil-9*H*-purin-2-il)-*N*-metil-1*H*-pirazol-4-carboxamida

$C_{15}H_{18}N_8O_5$



reparixinum

reparixin (2*R*)-2-[4-(2-methylpropyl)phenyl]-*N*-methylsulfonylpropanamide

réparixine (-)-(2*R*)-2-[4-(2-méthylpropyl)phényl]-*N*-(méthylsulfonyl)propanamide

reparixina (-)-(2*R*)-2-[4-(2-metilpropil)fenil]-*N*-(metilsulfonil)propanamida

$C_{14}H_{21}NO_3S$



retapamulinum

retapamulin (3a*S*,4*R*,5*S*,6*S*,8*R*,9*R*,9a*R*,10*R*)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propanocyclopenta[8]annulen-8-yl{[(1*R*,3*s*,5*S*)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl}acetate

rétapamuline [[(1*R*,3*s*,5*S*)-8-méthyl-8-azabicyclo[3.2.1]oct-3-yl]sulfanyl]acétate de (3a*S*,4*R*,5*S*,6*S*,8*R*,9*R*,9a*R*,10*R*)-6-éthényl-5-hydroxy-4,6,9,10-tétraméthyl-1-oxodécahydro-3a,9-propano-3a*H*-cyclopenta[8]annulén-8-yle

retapamulina [[(1*R*,3*s*,5*S*)-8-metyl-8-azabiciclo[3.2.1]oct-3-il]sulfanil]acetato de (3a*S*,4*R*,5*S*,6*S*,8*R*,9*R*,9a*R*,10*R*)-6-etenil-5-hidroxi-4,6,9,10-tetrametil-1-oxodecahidro-3a,9-propano-3a*H*-ciclopenta[8]anulen-8-ilo

$C_{30}H_{47}NO_4S$



revaprazanum

revaprazan — *N*-(4-fluorophenyl)-4,5-dimethyl-6-[(1*RS*)-1-methyl-3,4-dihydroisoquinolin-2(1*H*)-yl]pyrimidin-2-amine

révaprazan — *N*-(4-fluorophényl)-4,5-diméthyl-6-[(1*RS*)-1-méthyl-3,4-dihydroisoquinoléin-2(1*H*)-yl]pyrimidin-2-amine

revaprazán — *N*-(4-fluorofenil)-4,5-dimetil-6-[(1*RS*)-1-metil-3,4-dihidroisoquinolin-2(1*H*)-il]pirimidin-2-amina

$C_{22}H_{23}FN_4$



and enantiomer
et énantiomère
y enantiómero

rilpivirinum

rilpivirine — 4-{[4-({4-[(1*E*)-2-cyanoethenyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile

rilpivirine — 4-[[4-[[4-[(1*E*)-2-cyanoéthényl]-2,6-diméthylphényl]amino]pyrimidin-2-yl]amino]benzonitrile

rilpivirina — 4-[[4-[[4-[(1*E*)-2-cianoetenil]-2,6-dimetilfenil]amino]pirimidin-2-il]amino]benzonitrilo

$C_{22}H_{18}N_6$



ritobegronum

ritobegron — [4-(2-{[(1*R*,2*S*)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino}=ethyl)-2,5-dimethylphenoxy]acetic acid

ritobégron — acide [4-[2-[[(1*S*,2*R*)-2-hydroxy-2-(4-hydroxyphényl)-1-méthyléthyl]=amino]éthyl]-2,5-diméthylphénoxy]acétique

ritobegrón — ácido [4-[2-[[(1*R*,2*S*)-1-hidroxi-1-(4-hidroxifenil)prop-2-il]amino]etil]-2,5-dimetilfenoxi]acético

$C_{21}H_{27}NO_5$



robenacoxibum

robenacoxib — {5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl}acetic acid

robénacoxib — acide [5-éthyl-2-[(2,3,5,6-tétrafluorophényl)amino]phényl]acétique

robenacoxib — ácido [5-etil-2-(2,3,5,6-tetrafluoroanilino)fenil]acético

$C_{16}H_{13}F_4NO_2$



rostafuroxinum

rostafuroxin — 21,23-epoxy-24-nor-14β,5β-chola-20,21-diene-3β,14,17α-triol

rostafuroxine — 17-(furan-3-yl)-5β,14β-androstane-3β,14,17α-triol

rostafuroxina — 17-(furan-3-il)-5β,14β-androstano-3β,14,17α-triol

$C_{23}H_{34}O_4$



selodenosonum

selodenoson — 1-[6-(cyclopentylamino)-9*H*-purin-9-yl]-1-deoxy-*N*-ethyl-β-D-ribofuranuronamide

sélodénoson — 1-[6-(cyclopentylamino)-9*H*-purin-9-yl]-1-désoxy-*N*-éthyl-β-D-ribofuranuronamide

selodenosón — 1-[6-(ciclopentilamino)-9*H*-purin-9-il]-1-desoxi-*N*-etil-β-D-ribofuranuronamida

$C_{17}H_{24}N_6O_4$



taltobulinum

taltobulin (2*E*,4*S*)-4-{(2*S*)-*N*,3,3-trimethyl-2-[(2*S*)-3-methyl-2-(methylamino)-3-phenylbutanamido]butanamido}-2,5-dimethylhex-2-enoic acid

taltobuline acide (2*E*,4*S*)-4-[[(2*S*)-3,3-diméthyl-2-[[(2*S*)-3-méthyl-2-(méthylamino)-3-phénylbutanoyl]amino]butanoyl]méthylamino]-2,5-diméthylhex-2-énoïque

taltobulina ácido (2*E*,4*S*)-4-{(2*S*)-*N*,3,3-trimetil-2-[(2*S*)-3-metil-2-(metilamino)-3-fenilbutanamido]butanamido}-2,5-dimetilhex-2-enoico

$C_{27}H_{43}N_3O_4$



tandutinibum

tandutinib 4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}-*N*-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide

tandutinib 4-[6-méthoxy-7-[3-(pipéridin-1-yl)propoxy]quinazolin-4-yl]-*N*-[4-(1-méthyléthoxy)phényl]pipérazine-1-carboxamide

tandutinib 4-[6-metoxi-7-[3-(piperidin-1-il)propoxi]quinazolin-4-il]-*N*-[4-(1-metiletoxi)fenil]piperazina-1-carboxamida

$C_{31}H_{42}N_6O_4$



teglicarum

teglicar (3*R*)-3-[(tetradecylaminocarbonylamino]-4-(trimethylazaniumyl)=butanoate

téglicar (3*R*)-3-[(tétradécylcarbamoyl)amino]-4-(triméthylammonio)butanoate

teglicar (3*R*)-3-[(tetradecilcarbamoil)amino]-4-(trimetilamonio)butanoato

$C_{22}H_{45}N_3O_3$



telavancinum

telavancin

(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-3-(2-amino-2-oxoethyl)-10,19-dichloro-44-[(3-{[2-(decanylamino)ethyl]amino}-2,3,6-trideoxy-3-*C*-methyl-α-L-*lyxo*-hexopyranosyl-(1→2)-β-D-glucopyranosyl)oxy]-7,22,28,30,32-pentahydroxy-6-[(2*R*)-4-methyl-2-(methylamino)=pentanamido]-2,5,24,38,39-pentaoxo-29-{[(phosphonomethyl)=amino]methyl}-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-1*H*,22*H*-23,36-(epiminomethano)-8,11:18,21-dietheno-13,16:31,35-bis(metheno)[1,6,9]oxadiazacyclohexadecino[4,5-*m*][10,2,16]=benzoxadiazacyclotetracosine-26-carboxylic acid

télavancine

acide (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-3-(2-amino-2-oxoéthyl)-10,19-dichloro-44-[[2-*O*-[3-[[2-(décylamino)éthyl]amino]-2,3,6-tridésoxy-3-*C*-méthyl-α-L-*lyxo*-hexopyranosyl]-β-D-glucopyranosyl]oxy]-7,22,28,30,32-pentahydroxy-6-[[(2*R*)-4-méthyl-2-(méthylamino)pentanoyl]amino]-2,5,24,38,39-pentaoxo-29-[[(phosphonométhyl)amino]méthyl]-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tétradécahydro-23,36-(épiminométhano)-8,11:18,21-diéthéno-22*H*-13,16:31,35-diméthéno-1*H*,13*H*-[1,6,9]oxadiazacyclohexadécino=[4,5-*m*][10,2,16]benzoxadiazacyclotétracosine-26-carboxylique

telavancina

ácido (3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,36*R*,38a*R*)-3-(2-amino-2-oxoetil)-10,19-dicloro-44-[[2-*O*-[3-[[2-(decilamino)etil]amino]-2,3,6-tridesoxi-3-*C*-metil-α-L-*lixo*-hexopiranosil]-β-D-glucopiranosil]oxi]-7,22,28,30,32-pentahidroxi-6-[[(2*R*)-4-metil-2-(metilamino)=pentanoil]amino]-2,5,24,38,39-pentaoxo-29-[[(fosfonometil)amino]=metil]-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahidro-23,36-(epiminometano)-8,11:18,21-dieteno-22*H*-13,16:31,35-dimeteno-1*H*,13*H*-[1,6,9]oxadiazaciclohexadecino=[4,5-*m*][10,2,16]benzoxadiazaciclotetracosina-26-carboxílico

$C_{80}H_{106}Cl_2N_{11}O_{27}P$



tifuvirtidum

tifuvirtide — *N*-acetyl-L-tryptophyl-L-glutaminyl-L-glutamyl-L-tryptophyl-L-glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L-glutamyl-L-lysyl-L-asparagyl-L-glutamyl-L-tyrosyl-L-glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-glutamyl-L-tryptophyl-L-phenylalaninamide

tifuvirtide — acétyl-L-tryptophyl-L-glutaminyl-L-glutamyl-L-tryptophyl-L-glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-thréonyl-L-alanyl-L-leucyl-L-leucyl-L-glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L-glutamyl-L-lysyl-L-asparaginyl-L-glutamyl-L-tyrosyl-L-glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-séryl-L-leucyl-L-tryptophyl-L-glutamyl-L-tryptophyl-L-phénylalaninamide

tifuvirtida — acetil-L-triptofil-L-glutaminil-L-glutamil-L-triptofil-L-glutamil-L-glutaminil-L-lisil-L-isoleucil-L-treonil-L-alanil-L-leucil-L-leucil-L-glutamil-L-glutaminil-L-alanil-L-glutaminil-L-isoleucil-L-glutaminil-L-glutaminil-L-glutamil-L-lisil-L-asparaginil-L-glutamil-L-tirosil-L-glutamil-L-leucil-L-glutaminil-L-lisil-L-leucil-L-aspartil-L-lisil-L-triptofil-L-alanil-L-seril-L-leucil-L-triptofil-L-glutamil-L-triptofil-L-fenilalaninamida

$C_{235}H_{341}N_{57}O_{67}$



tilargininum

tilarginine — N^5-(methylamidino)-L-ornithine

tilarginine — acide (2*S*)-2-amino-5-(3-méthylguanidino)pentanoïque

tilarginina — N^5-(metilamidino)-L-ornitina

$C_7H_{16}N_4O_2$



topilutamidum

topilutamide — (2*RS*)-2-hydroxy-2-methyl-*N*-[4-nitro-3-(trifluoromethyl)phenyl]-3-[(trifluoroacetyl)amino]propanamide

topilutamide — (2*RS*)-2-hydroxy-2-méthyl-*N*-[4-nitro-3-(trifluorométhyl)phényl]-3-[(trifluoroacétyl)amino]propanamide

topilutamida — (2*RS*)-2-hidroxi-2-metil-*N*-[4-nitro-3-(trifluorometil)fenil]-3-[(trifluoroacetil)amino]propanamida

$C_{13}H_{11}F_6N_3O_5$



and enantiomer
et énantiomère
y enantiómero

torapselum

torapsel — 42-89-glycoprotein (human clone PMT21:PL85 P-selectin glycoprotein ligand fusion protein with immunoglobulin (human constant region)

torapsel — dimère de la protéine de fusion de la [48-proline]glycoprotéine (ligand 1 de la sélectine-P humaine)-(1-48)-peptide avec le peptide de 224 résidus, partie *C*-terminale de la chaîne lourde de l'immunoglobuline G1 humaine

torapsel — dímero de la proteína de fusión de la [48-prolina]glicoproteína (ligando 1 de la selectina-P humana)-(1-48)-péptido con el péptido de 224 residuos, parte *C*-terminal de la cadena pesada de la inmunoglobulina G1 humana

$C_{2726}H_{4186}N_{710}O_{846}S_{20}$



trodusqueminum

trodusquemine — (24*R*)-3β-{[3-({4-[(3-aminopropyl)amino]butyl}amino)propyl]amino}-7α-hydroxy-5α-cholestan-24-yl hydrogen sulfate

trodusquémine — hydrogénosulfate de (24*R*)-3β-[[3-[[4-[(3-aminopropyl)amino]butyl]=amino]propyl]amino]-7α-hydroxy-5α-cholestan-24-yle

trodusquemina — hidrogénosulfato de (24*R*)-3β-[[3-[[4-[(3-aminopropil)amino]butil]=amino]propil]amino]-7α-hidroxi-5α-colestan-24-ilo

$C_{37}H_{72}N_4O_5S$



vandetanibum

vandetanib *N*-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine

vandétanib *N*-(4-bromo-2-fluorophényl)-6-méthoxy-7-[(1-méthylpipéridin-4-yl)méthoxy]quinazolin-4-amine

vandetanib *N*-(4-bromo-2-fluorofenil)-7-[(1-metilpiperidin-4-il)metoxi]-6-metoxiquinazolin-4-amina

$C_{22}H_{24}BrFN_4O_2$



vestipitantum

vestipitant (2*S*)-*N*-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-*N*-methylpiperazine-1-carboxamide

vestipitant (+)-(2*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthylpipérazine-1-carboxamide

vestipitant (+)-(2*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorometil)fenil]etil]-2-(4-fluoro-2-metilfenil)-*N*-metilpiperazina-1-carboxamida

$C_{23}H_{24}F_7N_3O$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 51
Dénominations communes internationales recommandées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)

p. 94 **eptoterminum alfa**

eptotermin alfa — *replace the graphic formula by:*
eptotermine alfa — *remplacer la formule développée par:*
eptotermina alfa — *sustitúyase la fórmula desarrollada por la siguiente:*

STGSKQRSQN RSKTPKNQEA LRMANVAENS SSDQRQACKK
HELYVSFRDL GWQDWIIAPE GYAAYYCEGE CAFPLNSYMN
ATNHAIVQTL VHFINPETVP KPCCAPTQLN AISVLYFDDS
SNVILKKYRN MVVRACGCH

Recommended International Nonproprietary Names (Rec. INN): List 52
Dénominations communes internationales recommandées (DCI Rec.): Liste 52
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 52
(WHO Drug Information, Vol. 18, No. 3, 2004)

p. 248 **beminafilum**

beminafil — *replace the graphic formula by the following:*
béminafil — *remplacer la formule développée par la suivante:*
beminafilo — *sustitúyase la fórmula desarrollada por la siguiente:*



p. 264 **zanolimumabum**

zanolimumab — *delete the graphic formula*
zanolimumab — *supprimer la formule développée*
zanolimumab — *suprímase la fórmula desarrollada*

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.